Method of intranasal administration of granisetron

Details Method of intranasal administration of granisetron Method of intranasal administration of granisetron

2011-05-24

2011-05-24

Haghighatian, Mina (Department: 1616)

Drug, bio-affecting and body treating compositions

Effervescent or pressurized fluid containing

Organic pressurized fluid

C424S434000, C424S493000

Reexamination Certificate

active

07947257

ABSTRACT:
Compositions are provided for the intranasal administration of granisetron or a pharmaceutically acceptable salt thereof. Preferred compositions are in the form of an aqueous solution. Optionally, the compositions comprise chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention of nausea and/or vomiting.

REFERENCES:
patent: 5655517 (1997-08-01), Coffee
patent: 5897858 (1999-04-01), Haslwanter et al.
patent: 5929059 (1999-07-01), Sanger et al.
patent: 5952340 (1999-09-01), Sanger et al.
patent: 2002/0132803 (2002-09-01), Dedhiya et al.
patent: 1452964 (2003-11-01), None
patent: 1452965 (2003-11-01), None
patent: 0 376 385 (1990-07-01), None
patent: 0 470 872 (1992-02-01), None
patent: 1 250 925 (2002-10-01), None
patent: 95/28158 (1995-10-01), None
patent: WO 96/03142 (1996-02-01), None
patent: WO 98/30207 (1998-07-01), None
patent: WO 99/01498 (1999-01-01), None
patent: WO 03080021 (2003-10-01), None
patent: 2005060945 (2005-07-01), None
“Therapeutic Drugs”,Dollery(ed), 2ndedition, pp. G86-G90, (1999).
“The Complete Drug Reference”,Martindale, 33rdEdition Pharmaceutical Press, pp. 1227-1228, (2002).
Illum, “Nasal drug delivery: new developments and strategies”,Drug Discovery Today, vol. 7, No. 23, pp. 1184-1189, (2002).
Lipincott, “Remington: The Science and Practice of Pharmacy”, 20thEdition, Chapter 37, pp. 681-699 (2000).
J.T. Carstensen, “Pharmaceutical Priciples of Solid Dosage Forms”, Chapter 6, pp. 95-105, (1993).
A.T. Florence et al., “Physicochemical Principles of Pharmacy”, 3rdEdition, pp. 357-360, (1998).
A. Martin, “Physical Pharmacy”,Physical Chemical Principles in the Pharmaceutical Sciences, 4thEdition, pp. 516-519, (1993).
“Physician Desk Reference”, 57 Edition, (2003).
Anonymous, “Kytril (granisetron hydrochloride) Injection”, www.rocheusa.com, pp. 1-3 (Aug. 2002).
Anonymous, “Kytril (granisetron hydrochloride) Injection”, www.rocheusa.com, pp. 1-3 (Jun. 2001).
Kraut, L., et al., “Anti-Emetics for Cancer Chemotherapy-Induced Emesis: Potential of Alternative Delivery Systems”,Drugs, vol. 61, No. 11, pp. 1553-1562 (2001).
Aspden, T., et al, “Chitosan as a Nasal Delivery System: The Effect of Chitosan Solutions on in Vitro and in Vivo Mucociliary Transport Rates in Human Turbinates and Volunteers”,J. Pharm. Sciences, vol. 86, No. 4, pp. 509-513 (pp. 509-513) (Apr. 1997).
“Granisetron,” from Wikipedia, the free encyclopedia, (http://en.wikipedia.org/wiki/Granisetron) Feb. 20, 2007 printout, 2 pages.
Illum, L., et al., “Novel chitosan-based delivery systems for the nasal administration of a LHRH-analogue,” S.T.P. Pharma Sciences, 2000, vol. 10, 89-94 (1).
Hinchcliffe, Michael, et al. “Effect of chitosan on teh intranasal absorption of salmon calcitonin in sheep,” JPP 2005, 57:681-687.
L. Illum et al. “Intranasal Delivery of Morphine,” The Journal of Pharmacology and Experimental Therapeutics, 2002, vol. 301, No. 1, pp. 391-400.
International Preliminary Report on Patentability dated Jun. 7, 2006, with Written Opinion and International Search Report, 12 pages.
Official Action in Indian Application No. 643/MUMNP/2006, dated Apr. 23, 2009, 3 pages.
Official Action in Mexican Application No. PA/a/2006/006239, dated Feb. 16, 2009, 3 pages.
Official Action in Mexican Application No. PA/a/2006/00629, dated May 14, 2009, 3 pages.
Official Action in Mexican Application No. PA/a/2006/00629, dated Jul. 27, 2009, 3 pages.
Official Action in Israeli Application No. 176132, dated Mar. 19, 2009, 2 pages.
Official Action in Israeli Application No. 176132, dated Jun. 25, 2009, 2 pages.
Official Action in Israeli Application No. 176132, dated Sep. 24, 2009, 3 pages.
Official Action in Chinese Application No. 2004800398583, dated Jul. 30, 2008, 9 pages.
Examination Report in New Zealand Application No. 547848, dated Jan. 30, 2008, 1 page.
Examination Report in New Zealand Application No. 547848, dated Nov. 18, 2008, 1 page.
Examination Report and Notice of Acceptance of Complete Specification in New Zealand Application No. 547848, dated Apr. 16, 2009.
Letters Patent issued Aug. 13, 2009 for New Zealand Application No. 547848, 1 page.
Certificate of Grant of Patent for Singapore Application No. 200603779-0, 1 page.
Communication under Rule 71(3) EPC for European Application No. 04 798 713.6, dated Jan. 28, 2009, with attached amended application as allowed, 27 pages.
Illum, Lisbeth, et al. “Chitosan as a Novel Nasal Delivery System for Peptide Drugs,” Pharmaceutical Research, vol. 11, No. 8, (1994) pp. 1186-1189.
Examination Report in Australian Patent Application No. 2004296586 dated Apr. 21, 2010, 2 pages.
Decision on Rejection in Chinese Patent Application No. 200480039858.3, dated Jan. 22, 2010, 11 pages.

Affiliated with

Also associated with

Rating

Method of intranasal administration of granisetron does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of intranasal administration of granisetron, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of intranasal administration of granisetron will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2646495